SOLID TUMOR MALIGNANCIES

This early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…

This early-stage trial is testing an experimental virus called GO321, which is designed to infect and destroy cancer cells. The study involves adults with advanced solid tumors that have not responded to standard treatments. Participants receive GO321 as an injection directly int…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests a combination of two experimental drugs, FG-M108 and FG-B901, in people with advanced solid tumors that have a specific marker called Claudin 18.2. Participants must have tumors that have worsened despite standard treatments or for which no standard therapy exist…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This early-phase trial tests a personalized mRNA vaccine called RH125 in 36 people with advanced solid tumors who have no standard treatment options left. The vaccine is custom-made based on each patient's tumor mutations and is given alone or with a PD-1 blocker. The main goals …

This early-phase study tests a new radioactive tracer called [68Ga]Ga-FFD for PET imaging in healthy volunteers and people with solid tumors. The goal is to see if it is safe, where it goes in the body, and how well it spots tumors compared to standard imaging. Researchers will a…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This early-phase study tests whether adding malic acid (a natural fruit acid) to standard immunotherapy is safe for people with solid tumors like colorectal, lung, or melanoma cancer. About 30 participants will take malic acid by mouth while continuing their immunotherapy. The ma…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study will collect blood and swab samples from 160 adults with solid tumors who are about to start immunotherapy. The goal is to find a biological 'signature' that can predict which patients will develop severe immune-related side effects. If such a signature is found, it co…